Abbott Laboratories (ETR:ABL)

Germany flag Germany · Delayed Price · Currency is EUR
107.40
+0.92 (0.86%)
Jul 25, 2025, 5:35 PM CET
0.86%
Market Cap185.72B
Revenue (ttm)36.71B
Net Income (ttm)11.86B
Shares Outn/a
EPS (ttm)6.79
PE Ratio15.66
Forward PE23.00
Dividend2.10 (1.96%)
Ex-Dividend DateJul 15, 2025
Volume1,025
Average Volume554
Open107.10
Previous Close106.48
Day's Range107.10 - 107.70
52-Week Range90.00 - 134.14
Beta0.74
RSI39.43
Earnings DateJul 16, 2025

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism,... [Read more]

Sector Healthcare
Founded 1888
Employees 114,000
Stock Exchange Deutsche Börse Xetra
Ticker Symbol ABL
Full Company Profile

Financial Performance

In 2024, Abbott Laboratories's revenue was $41.95 billion, an increase of 4.59% compared to the previous year's $40.11 billion. Earnings were $13.35 billion, an increase of 134.19%.

Financial numbers in USD Financial Statements

News

Five years after COVID, pharma shares languish in US policy limbo

Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares remain in the doldrums, highlighting uncertainty over drug pricing policies...

2 days ago - Reuters

Best Dividend Kings: July 2025

14 Dividend Kings continue to outperform the S&P 500 in 2025. Dividend growth remains healthy, with one recent increase and a collective 2025 growth rate of 5.23%. Seventeen Dividend Kings currently a...

3 days ago - Seeking Alpha

Looking Into Abbott Laboratories's Recent Short Interest

Abbott Laboratories's (NYSE: ABT) short percent of float has fallen 5.83% since its last report. The company recently reported that it has 19.43 million shares sold short , which is 1.13% of all regu...

7 days ago - Benzinga

Analysts defend Abbott Labs' stock after Thursday's 'too punitive' sell-off

The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET.

7 days ago - CNBC

tech giants stumble as Tesla accelerates: Unpacking today's mixed market signals

📉 Technology Sector: Tech Giants Navigate Turbulence Today, the technology sector is showing signs of strain, with key players like Microsoft (MSFT) edging down by 0.17% and Oracle (ORCL) slipping by...

7 days ago - Forexlive

These Analysts Revise Their Forecasts On Abbott Following Q2 Results

Abbott Laboratories (NYSE: ABT) reported better-than-expected sales and profits in the second quarter, but dialed back earnings and growth projections for the rest of the year . The company reported ...

7 days ago - Benzinga

These Analysts Revise Their Forecasts On Abbott Following Q2 Results

Abbott Laboratories ABT reported better-than-expected sales and profits in the second quarter, but dialed back earnings and growth projections for the rest of the year.

7 days ago - Benzinga

Microsoft To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Friday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page . Jefferies...

7 days ago - Benzinga

Abbott CEO Robert Ford goes one-on-one with Jim Cramer

Abbott Chairman and CEO Robert Ford joins 'Mad Money' host Jim Cramer to talk quarterly results, lowering its full-year guidance, sale trends, and more.

8 days ago - CNBC Television

Didn't see the recovery in China we were expecting, says Abbott Labs CEO on lowering guidance

Abbott Chairman and CEO Robert Ford joins 'Mad Money' host Jim Cramer to talk quarterly results, lowering its full-year guidance, sale trends, and more.

8 days ago - CNBC Television

Abbott Laboratories CEO calls post-earnings stock decline 'a little bit of an overreaction'

Abbott Laboratories CEO Robert Ford unpacked his company's latest quarterly report in a Thursday interview with CNBC's Jim Cramer.

8 days ago - CNBC

Abbott Laboratories (ABT) Q2 2025 Earnings Call Transcript

Abbott Laboratories (NYSE:ABT) Q2 2025 Results Conference Call July 17, 2025 9:00 AM ET Company Participants Michael Comilla - Vice President of Investor Relations. Philip P. Boudreau - CFO & Executi...

8 days ago - Seeking Alpha

Abbott Narrows Its Outlook as COVID-19 Testing Demand Wanes. Its Stock Is Falling.

Abbott Laboratories shares slumped Thursday after the drugmaker narrowed its full-year outlook, even as it posted better-than-expected quarterly results, as demand for COVID-19 tests declines.

8 days ago - Investopedia

Tech sector rallies while healthcare faces downturn

Market Overview In today’s trading, tech stocks have emerged as the shining stars, displaying considerable gains against a backdrop of mixed sector performances. Conversely, the healthcare sector has ...

8 days ago - Forexlive

Abbott Laboratories Sheds Nearly 5% On A Rare Guidance Miss

Abbott stock toppled early Thursday after the health giant issued a light organic sales outlook for 2025, though beat quarterly calls.

8 days ago - Investor's Business Daily

Abbott Laboratories Issues Weak Earnings Forecast, Joins MP Materials And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

U.S. stock futures were mostly lower this morning, with the Dow futures falling around 0.2% on Thursday. Shares of Abbott Laboratories (NYSE: ABT) fell sharply in pre-market trading after the company...

8 days ago - Benzinga

Abbott Laboratories Issues Weak Earnings Forecast, Joins MP Materials And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

U.S. stock futures were mostly lower this morning, with the Dow futures falling around 0.2% on Thursday.

8 days ago - Benzinga

Abbott Labs Pares Outlook After Profit, Sales Gains

8 days ago - The Wall Street Journal

Abbott Laboratories (ABT) Q2 2025 sales and earnings beat estimates

Abbott Laboratories (NYSE: ABT) on Thursday announced financial results for the second quarter of fiscal 2025, reporting an increase in sales and adjusted profit. The results also exceeded Wall Street...

8 days ago - AlphaStreet

Abbott beats quarterly profit estimates on medical devices demand

Abbott beat Wall Street estimates for quarterly profit on Thursday, driven by strong demand for its medical devices including continuous glucose monitors.

8 days ago - Reuters